================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
----------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): March 4, 2004
BOSTON SCIENTIFIC CORPORATION
-----------------------------
(Exact name of registrant as specified in charter)
DELAWARE 1-11083 04-2695240
--------------- ----------- -------------
(State or other (Commission (IRS employer
jurisdiction of file number) identification no.)
incorporation)
ONE BOSTON SCIENTIFIC PLACE, NATICK, MASSACHUSETTS 01760-1537
-------------------------------------------------- ----------
(Address of principal executive offices) (Zip code)
Registrant's telephone number, including area code: (508) 650-8000
================================================================================
ITEM 5. OTHER EVENTS AND REQUIRED FD DISCLOSURE.
On March 4, 2004, Boston Scientific Corporation (the "Company") issued
a press release announcing that it received approval from the United States Food
and Drug Administration to market its TAXUS(TM) Express(2)(TM)paclitaxel-
eluting coronary stent system in the United States. A copy of the release is
attached to this report as exhibit 99.1.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS
(c) Exhibits.
99.1 Press Release issued by the Company dated March 4, 2004.
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of
1934, as amended, the Registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.
BOSTON SCIENTIFIC CORPORATION
Date: March 9, 2004 By: /s/ Lawrence J. Knopf
--------------------------------------------
Lawrence J. Knopf
Vice President and Assistant General Counsel